The table below lists the adverse events that have been reported in two double-blind, placebo- controlled trials in patients on chronic hemodialysis
induced by treatment with reduced glutathione and buthionine sulfoximine
GLP-1 medications work by binding to receptors that control hunger signals and glucose metabolism, creating a more comprehensive metabolic effect than phentermine alone
Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, Sonnenborn U, Nuding S, Bengmark S, Fellermann K, Schrder JM, Stange EF: NF-B- and AP-1-mediated induction of human -defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium
The drug pipeline continues to expand exponentially, including the more than 120 GLP-1 formulations in development as of April 2024
10.1016/j.ijcard.2017.03.103 15